CTOs on the Move

Modo Labs

www.modolabs.com

 
Modo Labs was founded in 2010 by Andrew Yu and a team of mobile developers from MIT. This team created the original MIT Mobile Framework with the vision to enable college students to easily create compelling, rich mobile websites and native applications using data and content from university back-end systems and other data repositories. That framework became Kurogo, a mobile-optimized middleware platform. In Japanese Kabuki Theater, Kurogo means the “stagehand” who serves the main characters in the background. Similarly, Kurogo works in the background to enable the rich mobile apps.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.modolabs.com
  • 100 Cambridgepark Dr. Suite 200
    Cambridge, MA USA 02140
  • Phone: 866.391.6636

Executives

Name Title Contact Details
Mark Peterson
 Senior Director of Technology Profile

Similar Companies

Ftg Software

Ftg Software is a Princeton, NJ-based company in the Software and Internet sector.

Digital Video Enterprises

Digital Video Enterprises is a Irvine, CA-based company in the Software and Internet sector.

Zenith Infoway

Zenith Infoway is a North Brunswick, NJ-based company in the Software and Internet sector.

Computing Insights

Computing Insights is a Escondido, CA-based company in the Software and Internet sector.

Teckro

Clinical research impacts us all. In modern healthcare, everything is made possible through research and development. But due to resource-intensive and costly processes, it has become increasingly difficult for clinical trials to sustain support, and be efficiently managed to completion. At Teckro, we are rethinking every element of clinical research – the people, the processes, the technologies used. By making it possible for all relevant information to be instantly accessible to every active member of a clinical trial and for the entire study teams to be connected effortlessly, we are broadening the possibilities of what they can achieve. This means drugs and treatments for the world`s most complex diseases are being developed quicker, and our long-term goal of continuously improving healthcare for everyone is realised.